Camber Pharmaceuticals Announces Addition of Sirolimus Oral Solution

Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.

Sirolimus Oral Solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years receiving renal transplants.

• Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
• Patients at high immunologic risk: use in combination with CsA and corticosteroids

Sirolimus Oral Solution 1 mg/mL is now available in a 60 mL bottle.

To find out more information on Sirolimus Oral Solution, please visit: www.camberpharma.com/sirolimus